Cancer means
nothing more than a death bed. When this deadly disease strikes, it brings with
it a huge burden in the form of surgery, radiations and chemotherapy. But,
nothing seems to give a respite from its deadly clutches. Being metastatic in
nature, the complications seem more intensifying when it turns back later even
after the treatment.
Hopes are
still not so bleak in the corner due to the discovery of a novel combination therapy,
aiming at doing away with the hard-to-kill blood cancers like leukemia and
their other types. The credit goes to a team of scientists at UC San Diego and
Oncternal Therapeutics to invent this approach.
The Development of The
Novel Drug Combination
An antibody has
been redefined as CIRMTUZUMUB for being initiated with the funding from CIRM, to
multiply its cancer treating abilities in compliance with ibrutinib, another conventional
anti-cancer drug.
Considering
the efficacy of ibrutinib, an international III stage clinical trial approved of
its performance capabilities to facilitate patients live longer without the
chances of metastasis of different types of leukemia in their bodies, including
chronic lymphocytic leukemia and small lymphocytic leukemia. The drug has
potential to treat patients with relapsed or refactory occurrences. In
addition, the application of the drug has an approval from the Food and Drug
Administration, so one can be assured of its safety.
However,
although it offers a better survival scopes for patients with leukemia, it does
not completely hinder the cancer cells from invading again. There are many
cancer stem cells, which are adamant and remain dormant during the treatment.
As a result, they do not die, and come back again only to proliferate and multiply
in greater numbers to infect the entire body. That is the only reason to combine cirmtuzumub
and ibrutinib together to cut back on the capacity of aggressive cancer cells
and prevent them from coming back.
How the Combinations of
Two Drugs Work to Prevent Hard-To-Kill Cancers?
Two drugs
have the potential to work in a different way. And when they are devised to
administer the patients together, they exert operations on their own way. CIRMTUZUMUB
being a monoclonal antibody aims at binding onto the CD20 antigen on the
leukemia cells. This capacity would help the drug induce cancer cell death,
while prompting the immune cells to wreak havoc on the cancer cells. On the
other hand, ibrutinib, suppresses the activity of a protein referred to as
Bruton tyrosine kinase, crucial to trigger a signaling pathway to encourage the
growth of B-cells. Hence, by restricting their action, the drug helps the regrowth
of lymphocytic cells.
How Are the Duo
Contrived to Kill Deadly Blood Cancers?
In order to help patients, eliminate the probabilities
of drug failure to kill all cancer cells, patients need to develop intolerance to
ibrutinib, or follow the drug intake for an indefinite period. The other drug cirmtuzumub
focuses to kill cancer stem cells which are tough to identify. However, cirmtuzumub
will work together with ibrutinib to contribute to the growth and survival of the
neoplastic-cell by inhibiting signaling pathways. And the process will help kill
the adamant cancer cells. At the same time, the patients become immune to avoid
any relapse and refactory in future, and also stop the further drug therapy.
Since, the
trial is at its early stage, the participants are likely to take two drugs
altogether, while others take only one at a time to determine the efficacy of
both the drugs.
If the
clinical trial becomes successful, we can expect a fast introduction of the
drug therapy to be in the clinical setting. And the therapy will be able to eradicate
hard-to-kill cancer cells and let patients live their lives to the fullest.
To know more
on new stem cell findings, log on to www.cordlifeindia.com.
This is my content and I wrote this as an assignment from APS digital. this is a non paid content. Please remove it immediately.
ReplyDelete